Literature DB >> 28716451

Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.

Trang D Trinh1, Evan J Zasowski1, Kimberly C Claeys1, Abdalhamid M Lagnf1, Shravya Kidambi1, Susan L Davis2, Michael J Rybak3.   

Abstract

Intensive care unit (ICU) admission is a risk for multidrug-resistant (MDR) Pseudomonas aeruginosa, but factors specific to critically ill pneumonia patients are not fully characterized. Objective was to determine risk factors associated with MDR P. aeruginosa pneumonia among ICU patients. This was a retrospective case-control study of P. aeruginosa pneumonia in the ICU; cystic fibrosis and colonizers were excluded. Risk factors included comorbid conditions and prior healthcare exposure (anti-pseudomonal antibiotics, hospitalizations, nursing home, P. aeruginosa colonization/infection, mechanical ventilation). Of 200 patients, 47 (23.5%) had MDR P. aeruginosa pneumonia. Independent predictors for MDR were ≥24h antibiotics in the preceding 90days (carbapenems, fluoroquinolones, and piperacillin-tazobactam) (odds ratio, 3.6 [95% CI, 1.6-8.1]) and nursing home residence (2.3 [1.1-4.9]). MDR P. aeruginosa remains prevalent among ICU patients with pneumonia. Given poor outcomes with delayed therapy, patients should be thoroughly assessed for prior anti-pseudomonal antibiotic exposure and nursing home residency.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multidrug resistance; Pneumonia; Pseudomonas; critically ill

Mesh:

Year:  2017        PMID: 28716451     DOI: 10.1016/j.diagmicrobio.2017.06.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

2.  Molecular Investigation of Outer Membrane Channel Genes Among Multidrug Resistance Clinical Pseudomonas Aeruginosa Isolates.

Authors:  Maytham Hassan Jasim Al-Thabhawee; Hussein Muttaleb Al-Dahmoshi
Journal:  Rep Biochem Mol Biol       Date:  2022-04

Review 3.  Risk Factors of Multidrug-Resistant Bacteria in Lower Respiratory Tract Infections: A Systematic Review and Meta-Analysis.

Authors:  Gang Chen; Kailiang Xu; Fangyuan Sun; Yuxia Sun; Ziyuan Kong; Bangjiang Fang
Journal:  Can J Infect Dis Med Microbiol       Date:  2020-06-30       Impact factor: 2.471

Review 4.  Interleukin-36 Cytokines in Infectious and Non-Infectious Lung Diseases.

Authors:  Hernán F Peñaloza; Rick van der Geest; Joel A Ybe; Theodore J Standiford; Janet S Lee
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

5.  Immune Efficacy of different immunization doses of divalent combination DNA vaccine pOPRL+pOPRF of Pseudomonas aeruginosa.

Authors:  Qiang Gong; Mengdie Ruan; Mingfu Niu; Cuili Qin
Journal:  J Vet Med Sci       Date:  2021-11-11       Impact factor: 1.267

6.  XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?

Authors:  Paola Del Giacomo; Francesca Raffaelli; Angela Raffaella Losito; Barbara Fiori; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-02-01

7.  Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019.

Authors:  Sibylle H Lob; Daryl D DePestel; C Andrew DeRyke; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Open Forum Infect Dis       Date:  2021-06-16       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.